Role of coronary angiogram before transcatheter aortic valve implantation

Table 1 Baseline clinical characteristics, stratified according to whether patients had invasive angiogram before their transcatheter aortic valve implantation procedure

	Whole group (n = 348)	No coronary angiogram group (n = 194)	Coronary angiogram group (n = 154)	P value
Age (mean ± SD)	81 ± 7	82 ± 7	81 ± 7	NS
Male gender, n (%)	197 (57)	109 (56)	88 (57)	NS
Obesity, n (%)	83 (34)	43 (31)	40 (37)	NS
Hypertension, n (%)	136 (55)	79 (57)	57 (53)	NS
NYHA III/IV, n (%)	232 (67)	127 (66)	105 (68)	NS
Diabetes, n (%)	68 (20)	39 (20)	29 (19)	NS
Smoking history, n (%)	166 (48)	94 (49)	72 (47)	NS
Previous MI, n (%)	38 (11)	16 (8)	22 (14)	NS
Previous PCI, n (%)	52 (15)	20 (10)	32 (21)	< 0.01
Previous CABG, n (%)	43 (12)	33 (17)	10 (7)	< 0.01
COPD, n (%)	58 (17)	34 (18)	24 (16)	NS
CVA/TIA, n (%)	29 (8)	14 (7)	15 (10)	NS
AF, n (%)	83 (24)	47 (24)	36 (23)	NS
PVD, n (%)	55 (16)	24 (12)	31 (20)	< 0.05
Creatinine (mean ± SD)	112 ± 97	114 ± 117	110 ± 65	NS
Elective admission, n (%)	271 (78)	149 (77)	122 (79)	NS

MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass graft; COPD: Chronic obstructive pulmonary disease; CVA: Cerebrovascular event; TIA: Transient ischaemic attack; AF: Atrial fibrillation; PVD: Peripheral vascular disease; NS: No significant difference. Obesity was defined as body mass index > 30 kg/m².

Table 2 Echocardiographic and procedural characteristics, stratified according to whether patients had invasive angiogram before their transcatheter aortic valve implantation procedure

	Whole group (n = 348)	No coronary angiogram group (n = 194)	Coronary angiogram group (n = 154)	P value
Peak gradient (mean ± SD)	74 ± 23	73 ± 22	74 ± 24	NS
Mean gradient (mean ± SD)	43 ±15	44 ±15	43 ±15	NS
Valve area (mean ± SD)	0.70 ± 0.20	0.71 ± 0.18	0.69 ± 0.22	NS
Preserved LV function, n (%)	274 (79)	158 (81)	116 (75)	NS
Moderate MR, n (%)	35 (10)	20 (10)	15 (10)	NS
PA pressure (mean ± SD)	39 ± 20	40 ± 15	39 ± 25	NS
Indication for AR or mixed AoV disease, n (%)	19 (6)	9 (5)	10 (7)	NS
Bioprosthetic valve, n (%)	17 (5)	14 (7)	3 (2)	< 0.05
GA, n (%)	23 (7)	4 (2)	19 (12)	< 0.01
BAV, n (%)	34 (10)	15 (8)	19 (12)	NS
Transfemoral approach, n (%)	311 (89)	183 (94)	128 (83)	< 0.01
Balloon-expanding, n (%)	295 (85)	161 (83)	134 (87)	NS
Valve size (> 23 mm), n (%)	222 (64)	125 (64)	97 (63)	NS

LV: Left ventricle; MR: Mitral regurgitation; PA: Pulmonary pressure; AR: Aortic regurgitation, AoV: Aortic valve disease; GA: General anaesthesia; BAV: Balloon valvuloplasty performed for pre-dilatation; NS: No significant difference.

Table 3 Clinical endpoints following transcatheter aortic valve implantation procedure

	Whole group (n = 348)	No coronary angiogram group (n = 194)	Coronary angiogram group (n = 154)	P value
Primary endpoint, n (%)	78 (22.4)	44 (22.6)	33 (22.2)	NS
Death, n (%)	63 (18.1)	37 (19.0)	26 (17.0)	NS
Myocardial infarction, n (%)	8 (2.3)	2 (1.0)	6 (3.9)	NS
Readmission with heart failure, n (%)	14 (4)	12 (6.2)	2 (1.3)	< 0.05
Coronary angiogram post valve intervention, n (%)	10 (2.9)	1 (0.5)	9 (5.8)	< 0.01
Death & myocardial infarction, n (%)	69 (19.8)	38 (19.5)	31 (20.3)	NS
Death & readmission with heart failure, n (%)	70 (20.1)	43 (22.1)	27 (17.6)	NS
Myocardial infarction & readmission with heart failure, n (%)	21 (6)	13 (6.7)	8 (5.2)	NS

Primary endpoint was defined as a composite of death, myocardial infarction, revascularisation, and readmission with heart failure. NS: No significant difference.